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Abstract
Background: Studies aiming to assess genetic susceptibility for impaired lung function levels upon exposure to
environmental tobacco smoke (ETS) have thus far focused on candidate-genes selected based on a-priori knowledge
of potentially relevant biological pathways, such as glutathione S-transferases and ADAM33. By using a hypothesis-free
approach, we aimed to identify novel susceptibility loci, and additionally explored biological pathways potentially
underlying this susceptibility to impaired lung function in the context of ETS exposure.
Methods: Genome-wide interactions of single nucleotide polymorphism (SNP) by ETS exposure (0 versus ≥1 h/day) in
relation to the level of forced expiratory volume in one second (FEV1) were investigated in 10,817 subjects from the
Dutch LifeLines cohort study, and verified in subjects from the Swiss SAPALDIA study (n = 1276) and the
Dutch Rotterdam Study (n = 1156). SNP-by-ETS exposure p-values obtained from the identification analysis
were used to perform a pathway analysis.
Results: Fourty Five SNP-by-ETS exposure interactions with p-values <10−4 were identified in the LifeLines
study, two being replicated with nominally significant p-values (<0.05) in at least one of the replication
cohorts. Three pathways were enriched in the pathway-level analysis performed in the identification cohort
LifeLines, i.E. the apoptosis, p38 MAPK and TNF pathways.
Conclusion: This unique, first genome-wide gene-by-ETS interaction study on the level of FEV1 showed that
pathways previously implicated in chronic obstructive pulmonary disease (COPD), a disease characterized by
airflow obstruction, may also underlie susceptibility to impaired lung function in the context of ETS exposure.
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Background
Detrimental effects of environmental tobacco smoke
(ETS) exposure on the level of lung function have been
shown in a number of studies. [1–3] Moreover, polymor-
phisms in several genes such as the glutathione S-
transferases (GSTs), [4, 5] and ADAM33, [6] interact
with ETS exposure, thereby negatively affecting the level
and decline of lung function. In other words, ETS expos-
ure has differential effects in subjects carrying mutant
alleles compared to wild type alleles. Thus far, studies
assessing interactions between genetic variants and ETS
exposure were driven by a-priori knowledge of biological
pathways, for example detoxification of noxious particles
and gases by proteins such as the glutathione S-
transferases.
In contrast, genome-wide interaction (GWI) studies
are hypothesis-free and may yield novel loci in addition
to those already known to be associated with impaired
lung function directly (i.e. in genome-wide association
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studies without taking exposure into account). [7] Find-
ings from such studies may provide novel insights in
molecular pathways underlying disease pathogenesis, e.g.
the development of chronic obstructive pulmonary dis-
ease (COPD) characterized by airflow obstruction. In
this first genome-wide gene-by-ETS exposure study, we
aimed to identify novel susceptibility loci, and addition-
ally explored biological pathways potentially underlying
this susceptibility to impaired forced expiratory volume
in one second (FEV1) in the context of ETS exposure
during adulthood.
Methods
Cohort and measurements
Subjects from the baseline investigation of the LifeLines
cohort study (2006–2011), a multi-disciplinary prospect-
ive population-based cohort study examining health and
health-related behaviour of persons living in the North
East region of the Netherlands, were included as identifi-
cation cohort. [8, 9] To verify our initial findings we
included subjects from two independent general
population-based cohorts, the Swiss SAPALDIA study,
[10] and the Dutch Rotterdam Study. [11] More de-
tailed description of the cohorts, spirometric measure-
ments and genotyping can be found in the online
supplement (Additional file 1: Methods).
Exposure assessment
In the LifeLines and SAPALDIA studies ETS exposure
was determined by the response to the question “how
many hours per day are you exposed to other person’s
tobacco smoke?”. In the Rotterdam study the question
was similar, yet more specifically focused on exposure at
home “at home, how many hours per day are you ex-
posed to other person’s tobacco smoke?”. In all three co-
horts, subjects were classified as ETS exposed if they
reported at least 1 h/day (≥1 h/day) of exposure to other
person’s tobacco smoke, and as non-exposed when self-
reported ETS exposure was 0 h/day. Subjects that re-
ported between 0 and 1 h/day of ETS exposure were ex-
cluded in order to have a clear exposure contrast.
SNP-by-ETS exposure interactions
First, interactions of 227,981 genotyped SNPs with daily
ETS exposure and their association with FEV1 were
assessed in the identification cohort LifeLines. SNPs
were tested in an additive genetic model including SNP,
ETS exposure and the SNP-by-ETS exposure interaction.
All models were adjusted for sex, age, height, ever smok-
ing and pack years using linear regression models in the
software package PLINK, version 1.07. [12] SNPs with p-
values for the SNP-by-ETS interaction <10−4 were
taken further for verification in the two independent
cohorts, the SAPALDIA study and the Rotterdam
Study (Additional file 1: Methods).
Finally SNP-by-ETS interaction effects from the three
cohorts for the SNPs identified in the identification ana-
lysis were meta-analyzed using fixed effects models with
effect estimates weighted by the inverse of the standard
errors using software package METAL. [13] We selected
SNP-by-ETS interactions with the same direction of
interaction in all three cohorts and considered interac-
tions with p-values < 0.05 in at least one of the two rep-
lication cohorts significantly replicated. SNP annotation
was performed using HaploReg version 4.1. [14].
Pathway analysis
All p-values for SNP-by-ETS interactions from the iden-
tification cohort LifeLines were used in the pathway ana-
lysis using the online improved gene set enrichment
analysis tool i-GSEA-4-GWAS. [15] All log transformed
p-values for SNPs 100 kb upstream and downstream of
each gene were used to represent that specific gene.
Each gene was represented by the lowest SNP p-value
annotated to that gene. These SNP p-values were used
to rank the genes, and the proportion of significant
genes as a number of the total amount of genes (gene
set) belonging to a pathway was calculated. Based on the
rank, p-values were calculated for the association be-
tween the total gene set/pathway and the outcome. Add-
itionally false discovery rate (FDR) corrected p-values
were calculated. Gene sets/pathways with FDR corrected
p-values < 0.25 are regarded as suggestively associated
with the outcome, whereas FDR p-values < 0.05 are
regarded as highly confident for an association with the
outcome. [15].
Results
Descriptive statistics
In the LifeLines study, complete data on all covariates
was available for 11,187 subjects. 370 subjects (3%) were
excluded because they had self-reported ETS exposure
between 0 and 1 h per day. Finally, the analysis included
10,817 subjects, of which 2473 subjects (23%) reported
at least one hour of ETS exposure per day (Table 1). In
the verification cohorts, complete data was available for
1276 subjects in the SAPALDIA study (23% being ETS
exposed) and 1156 subjects in the Rotterdam study (19%
being ETS exposed) (Table 1).
SNP-by-ETS exposure interactions
P-values for each SNP-by-ETS exposure interaction in
association with the level of FEV1 in the identification
analysis are shown in a Manhattan plot (Fig. 1). A total
of 45 SNPs had interaction p-values <10−4 in the
identification cohort LifeLines (Additional file 2: Table S1)
and were taken further for verification in the two
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independent cohorts. Of these 45 identified SNPs,
rs4421160 was not available in the SAPALDIA study and
two other SNPs, rs13282467 and rs743262, were not avail-
able in the Rotterdam Study.
Of the 45 identified SNP-by-ETS interactions, nine
had the same direction of effect in all three cohorts. For
all nine interactions there was little indication of hetero-
geneity between the cohorts (I2 for all interactions < 30)
(Table 2). Two of these nine interactions were nominally
significant (rs11950494 and rs2090789, p < 0.05) in one
of the two verification cohorts. None of these nine inter-
actions reached genome-wide significance in the meta-
analysis of all three cohorts (i.e. Bonferroni-corrected
threshold for 227,981 SNPs tested in the initial identifi-
cation analysis = p < 2.26*10−7) (Table 2).
Pathway analysis
Of all SNP-by-ETS interactions included in the identifi-
cation analysis in the LifeLines study, p-values of
165,298 interactions were mapped to 15,243 genes and
231 gene sets/pathways. Pathway analysis showed one
significant (FDR p-value < 0.05) and two suggestively
enriched pathways (FDR p-value < 0.25) (Table 3). The
most significant, i.e. the apoptosis pathway, includes 71
genes of which 54 were present in the identification ana-
lysis and 23 were significantly associated with the out-
come (Table 4). The two suggestively associated pathways
were the p38 MAPK pathway (Table 5) and tumor necrosis
factor (TNF) pathway (Table 6), with 16 genes and 9 genes
from the SNP-by-ETS exposure interaction analysis that
were significantly associated with the outcome, respectively.
Table 1 Characteristics of the subjects included from the LifeLines, SAPALDIA and Rotterdam cohort studies
LifeLines (identification) SAPALDIA (replication) Rotterdam Study 1 (replication)
N with complete data 10,817 1276 1156
ETS exposed (≥1 h/day), n (%) 2473 (23) 296 (23) 219 (19)
FEV1 (ml), mean (sd) 3401 (825) 3153 (864) 2199 (653)
FEV1% of predicted
a, mean (sd) 102 (14) 96 (16) 104 (23)
FEV1/FVC (%), mean (sd) 76 (7) 74 (8) 75 (8)
FEV1/FVC < 70%, n (%) 1600 (15) 327 (26) 228 (20)
GOLD2+, n (%) 417 (4) 134 (11) 133 (12)
Use of medication for obstructive airway diseases#, n (%) 676 (6) 164 (18)$ 106 (9)
Males, n (%) 4473 (41) 611 (48) 495 (43)
Age, median (min-max) 47 (18–88) 52 (29–72) 78 (72–95)
Ever smokers, n (%) 6266 (58) 703 (55) 771 (67)
Pack years in ever smokers, median (min-max) 10 (0–100) 12 (0–130) 18 (0–145)
ETS environmental tobacco smoke, FEV1 forced expiratory volume in one second, FVC forced vital capacity
aFEV1 as % of predicted following the reference equations of Quanjer et al. (1993) in LifeLines, [28] and GLI in Rotterdam study
GOLD2+ defined as FEV1/FVC < 70% and FEV1% of predicted <80%
#ATC code R03, $ In SAPALDIA missing data for n = 377
Fig. 1 Manhattan plot showing SNP-by-ETS exposure interactions on the level of FEV1 in the identification cohort LifeLines. The blue line depicts
the threshold for selection of SNPs (p = 10−4) and the red line the genome-wide significance level (p = 2.26*10−7)
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Discussion
The current study is the first to explore SNP-by-ETS ex-
posure interactions on the level of FEV1 during adult-
hood in a hypothesis-free genome-wide manner. We
extended our findings to pathway level analysis and
showed that several pathways, i.e. the apoptosis, p38
MAPK and TNF pathways, may be underlying suscepti-
bility to impaired FEV1 in the context of ETS exposure.
The SNP with the most significant interaction in the
identification cohort was located in the gene coding for
KCNH1, also known as ether-à-go-go (EAG1). KCNH1
is a voltage-gated potassium channel that is highly
expressed on mast cells and macrophages in germinal
centers of reactive lymph nodes, [16] which may indicate
its involvement in immune responses. Moreover, both
mRNA and protein expression of KCNH1 were up-
regulated during epithelial-to-mesenchymal transition
(EMT) of human lung tumor cells induced by TGFβ1.
[17] Increased expression of EMT markers has been ob-
served in the airways of smokers, especially those with
COPD. [18] Although one SNP in KCNH1 (rs7526579)
had the same direction of interaction effect in all three
cohorts, it did not reach genome-wide significance after
meta-analysis and did not reach nominal significance in
at least one of the verification cohorts. Findings, there-
fore, remain speculative.
Two SNPs-by-ETS interactions identified in the Life-
Lines study had nominally significant p-values in at least
one of the verification cohorts, i.e. rs11950494 in
SAPALDIA and rs2090789 in the Rotterdam Study. SNP
rs11950494 is located in the gene actin beta-like 2
(ACTBL2) and rs2090789 is located in a predicted non-
coding RNA LOC100128993. Both genes are expressed
in lung tissue (genecards.org), however, at current little
is known about their biological function in general or
relevance to lung function specifically.
In the current study, we used a large and well doc-
umented homogeneous cohort of a general popula-
tion, i.e. the LifeLines study, to assess SNP-by-ETS
exposure interactions. We used a liberal p-value threshold
(p < 10−4) in the identification analysis and attempted to
verify the SNP-by-ETS exposure interactions in two inde-
pendent cohorts, the SAPALDIA and Rotterdam studies.
Only 2 SNP-by-ETS exposure interactions were replicated
with a nominal p-value and with the same direction of ef-
fect, which is less than expected based on chance only (i.e.
5% of 45 SNPs = 2.25). Moreover, none of the SNPs
reached the Bonferroni-corrected threshold for genome-
wide significance (p-value = 2.19*10−7). Therefore inter-
pretation of the results remains difficult and the implica-
tions of the outcomes uncertain. The replication cohorts
were relatively small, which may have limited the power
Table 2 Meta-analyzed SNP-by-ETS exposure interactions (additive for effect allele A1) with consistent direction of interaction effects
in the three cohorts. Interactions effects for the independent cohorts LifeLines (identification), SAPALDIA (verification) and the Rotterdam
Study (verification) are also shown
Meta-analysis LifeLines SAPALDIA Rotterdam Study
SNP A1 Gene (RefSeq) Bint SEint P-value Direction I
2 Bint SEint P-value Bint SEint P-value Bint SEint P-value
rs11950494 G ACTBL2 (intronic) −115 25 4.06E-06 — 0 −110 28 7.60E-05 −162 73 2.73E-02 −96 88 2.75E-01
rs2859741 T GRIK3 (9.5 kb 5′) 59 13 6.78E-06 +++ 0 69 15 3.86E-06 21 31 4.86E-01 38 51 4.61E-01
rs11153056 C PDSS2 (intronic) 67 15 7.59E-06 +++ 20 72 16 1.36E-05 69 44 1.15E-01 1 58 9.91E-01
rs7831729 C SNX31 (15 kb 5′) −76 17 1.12E-05 — 0 −80 19 3.03E-05 −43 49 3.88E-01 −79 62 1.99E-01
rs2084386 C PAK2 (intronic) 90 21 1.47E-05 +++ 7 95 23 2.74E-05 28 71 6.90E-01 101 74 1.74E-01
rs9386622 T PDSS2 (intronic) 63 15 1.67E-05 +++ 25 65 16 8.08E-05 82 43 5.55E-02 22 51 6.74E-01
rs2090789 A LOC100128993 (intronic) −53 13 3.95E-05 — 0 −60 15 6.54E-05 −9 31 7.71E-01 −99 50 4.77E-02
rs7526579 C KCNH1 (intronic) −67 16 4.37E-05 — 29 −75 18 4.88E-05 −18 44 6.79E-01 −72 60 2.32E-01
rs7030493 T TMEM2 (intronic) −101 25 4.99E-05 — 0 −112 27 3.24E-05 −42 86 6.25E-01 −30 98 7.59E-01
Table 3 Significantly (FDR p-value <0.05) and suggestively (FDR p-value <0.25) enriched pathways based on genome-wide interaction
SNP-by-ETS exposure p-values within 100 kb of the gene using i-GSEA-4-GWAS [15]
Pathway/Gene set
name
Description FDR corrected
p-value
Significant genes/ Selected
genes/All genes
Apoptosis Apoptosis is a distinct form of cell death that is functionally and morphologically
different from necrosis.
0.003 22/54/71
P38 MAPK pathway The Rho family GTPases activate the p38 MAPKs under environmental stress or in
the presence of pro-inflammatory cytokines.
0.063 16/33/40
Tumor Necrosis
Factor pathway
Tumor necrosis factor is a pro-inflammatory cytokine that activates NF-kB and c-
Jun.
0.081 9/22/29
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to significantly replicate our findings. Another reason for
not finding significant interaction effects may be the ra-
ther crude assessment of ETS exposure. In general, meas-
uring ETS exposure during adulthood is difficult,
especially when using self-reports. Thus far, no GWI stud-
ies on ETS exposure during adulthood have been pub-
lished, suggesting that either no studies have been
performed, or that publication bias exists due to null find-
ings. There were slight differences in characteristics be-
tween the cohorts, i.e. enrichment with asthmatics in
SAPALDIA (40% asthmatics) and the older mean age of
subjects in the Rotterdam Study. However, sensitivity ana-
lysis in the identification cohort suggested that effects esti-
mates for the two marginally replicated SNPs did not
change when only non-asthmatics were included. More-
over, SNP-by-ETS interaction effects rather get more than
less pronounced in older (≥50 years) compared to younger
subjects (<50 years) (data not shown). Interestingly, a final
sensitivity analysis showed that associations of these two
SNP-by-ETS interactions with FEV1, did only remain in
subjects without airway obstruction (FEV1/FVC ≥ 70%)
(data not shown), suggesting that genetic susceptibility to
effects of ETS is less important when already having air-
way obstruction.
In addition to single SNP analysis we performed a
pathway analysis based on interaction p-values in the
LifeLines study. Compared to single SNP analysis,
Table 4 Genes significantly enriched in the apoptosis pathway.
Effect estimates (Bint in mL FEV1) and p-values from the SNP-
by-ETS exposure interaction analysis in LifeLines are given
Significant genes in the Apoptosis pathway
Pathway analysis SNP-by-ETS
exposure interaction
Gene Name SNP -log(P-value) Bint FEV1 (ml) P-value
APAF1 rs12581724 4.23 −111 5.88E-05
MYC rs7829529 3.00 109 1.00E-03
IRF2 rs3775574 2.74 −47 1.81E-03
BNIP3L rs3808578 2.63 −70 2.35E-03
CASP9 rs4645983 2.52 −52 3.00E-03
BCL2L11 rs1877330 2.47 85 3.40E-03
JUN rs2716129 2.45 −43 3.52E-03
MAP2K4 rs2013868 2.11 −51 7.73E-03
TNFRSF10B rs11784599 1.91 −48 1.24E-02
MAPK10 rs7688651 1.86 38 1.39E-02
FAS rs1926189 1.75 54 1.76E-02
GZMB rs1957519 1.75 −62 1.79E-02
NFKBIE rs513688 1.72 37 1.91E-02
TNFRSF1B rs235214 1.67 50 2.14E-02
BCL2L1 rs6060870 1.64 42 2.29E-02
FADD rs10751209 1.57 −33 2.71E-02
BAK1 rs210138 1.55 42 2.80E-02
BCL2 rs1801018 1.50 32 3.17E-02
CASP8 rs3769823 1.47 35 3.40E-02
HRK rs4767462 1.46 −63 3.43E-02
TNFRSF21 rs9463313 1.46 37 3.46E-02
NFKB1 rs2085548 1.38 33 4.17E-02
Table 5 Genes significantly enriched in the p38 MAPK pathway.
Effect estimates (Bint in mL FEV1) and p-values from the SNP-by-
ETS exposure interaction analysis are given
Significant genes in the p38 MAPK pathway
Pathway analysis SNP-by-ETS exposure
interaction
Gene Name SNP -log(P-value) Bint FEV1 (ml) P-value
MYC rs7829529 4.23 109 1.00E-03
TGFBR1 rs12686783 3.00 71 1.39E-03
MAP2K6 rs2716227 2.74 −45 2.36E-03
MAP2K4 rs2013868 2.63 −51 7.73E-03
CREB1 rs722761 2.52 −38 1.38E-02
MAPK14 rs851023 2.47 52 1.47E-02
MEF2A rs7164257 2.45 −55 1.80E-02
MAP3K9 rs731571 2.11 42 2.01E-02
TGFB2 rs2798631 1.91 35 2.05E-02
HSPB1 rs2908201 1.86 −39 2.22E-02
MAX rs2763887 1.75 −67 3.32E-02
MAP3K7 rs205349 1.75 50 3.38E-02
MAP3K5 rs2237268 1.72 32 3.41E-02
PLA2G4A rs10489409 1.67 −53 3.81E-02
MAPKAPK2 rs11119447 1.64 −32 3.87E-02
HMGN1 rs2836992 1.57 −31 3.93E-02
Table 6 Genes significantly enriched in the Tumor Necrosis
Factor pathway. Effect estimates (Bint in mL FEV1) and p-values
from the SNP-by-ETS exposure interaction analysis in LifeLines
are given
Significant genes in the Tumor Necrosis Factor pathway
Pathway analysis SNP-by-ETS exposure
interaction
Gene Name SNP -log(P-value) Bint FEV1 (ml) P-value
JUN rs2716129 2.45 −43 3.52E-03
MAP2K4 rs2013868 2.11 −51 7.73E-03
TNFAIP3 rs11970361 1.94 −95 1.14E-02
NFKBIE rs513688 1.72 37 1.91E-02
TNFRSF1B rs235214 1.67 50 2.14E-02
FADD rs10751209 1.57 −33 2.71E-02
MAP3K7 rs205349 1.47 50 3.38E-02
CASP8 rs3769823 1.47 35 3.40E-02
NFKB1 rs2085548 1.38 33 4.17E-02
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pathway analysis may have increased power to detect
genetic associations of the phenotype with a gene set/
pathway. [19] Three pathways were significantly or sug-
gestively enriched, i.e. the apoptosis, p38 MAPK and
TNF pathways. Interestingly all three pathways may mu-
tually interact and have been previously implicated in
the pathogenesis of COPD, a disease caused by an ab-
normal inflammatory response to noxious particles and
gases leading to airflow obstruction.
Apoptosis is a programmed form of cell death. Previ-
ous investigations within the SAPALDIA study have
found suggestive evidence that genetic variation in the
apoptosis pathway modifies the effect of pack years
smoked on the decline of FEV1. [20] An imbalance be-
tween apoptosis and proliferation of alveolar epithelial
and endothelial cells has been observed in the lungs of
patients with COPD. [21] Apoptosis is regulated by vari-
ous pathways. One of the pathways is a response to
extracellular signals by binding of members of the tumor
necrosis family, such as TNF-alpha with death receptor
TNF-receptor 1. [21] For example, cigarette smoke ex-
posure was shown to increase TNF-alpha expression.
[22] This interaction between the different pathways was
also reflected by the substantial overlap in genes
enriched in the TNF-alpha (Table 6) and apoptosis path-
ways (Table 4) in the pathway analysis. Another pro-
apoptotic pathway responds to physical and chemical
stressors via the release of cytochrome C by mitochon-
dria. Subsequent formation of an apoptosome activates
several caspases which eventually initiate apoptosis.
Interestingly, we identified an intronic SNP in APAF1
that interacted with ETS exposure (p-value = 5.88*10−5)
in the identification cohort LifeLines, the expressed pro-
tein of this gene is part of this apoptosome initiating
apoptosis (Additional file 1: Tables S1 and Table 4).
However, this SNP-by-ETS exposure interaction was not
replicated in the SAPALDIA or Rotterdam study.
The TNF pathway was suggestively enriched in the
pathway analysis. TNF-alpha is a cytokine playing an im-
portant role in inflammation through its activation of
several downstream signaling cascades, amongst others
the p38 MAPK pathway. Levels of TNF-alpha have been
shown to be increased in sputum of COPD patients
compared to both non-smoking and smoking controls,
and in response to air pollution exposure. [23, 24] The
second suggestively enriched pathway was the p38 mito-
gen activated protein kinase (MAPK) pathway, this path-
way has also been implicated in the development and/or
maintenance of a number of chronic airway inflammatory
diseases such as COPD. [25] The p38 MAPK pathway is
activated by various environmental stressors, growth fac-
tors and cytokines and in turn regulates the expression of
inflammatory cytokines such as TNF-alpha and may initi-
ate apoptosis. [26] Increased activation of p38 MAPK was
seen in alveolar walls and alveolar macrophages of
COPD patients compared to non-smoking and smok-
ing controls. [27].
Conclusion
The current study is the first to explore gene-by-ETS in-
teractions related to the level of FEV1 in a hypothesis-
free genome-wide manner. Findings from the single SNP
analysis remain uncertain, yet our pathway analysis sug-
gests that pathways previously implicated in COPD
pathogenesis may, as well, underlie susceptibility to im-
paired lung function in the context of ETS exposure.
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